Optimizing Care for Kidney Transplant Recipients Who Experience Graft Loss

Study Lead

Dr. Shaifali Sandal

Research Institute of the McGill University Health Centre

Overview

The purpose of this study is to understand the experiences and coping strategies of KT patients who experience a graft loss. We also want to understand the experiences and coping strategies of family members and close friends who have helped to support their loved one during the experience of graft loss. The broader goal of this study is to understand how care could be improved for patients who experience graft loss, and to provide guidance for how healthcare teams should approach treatment options following the loss of a graft.

Participant Commitment:

One 60-minute interview. Participants will be asked open-ended questions about their experience as a caregiver for someone losing a kidney transplant, and questions about their perspective on the care received and how they think it could be improved.

Eligibility

We are recruiting caregivers over the age of 18 who have cared for a kidney transplant recipient throughout the experience of graft loss. Caregivers can have any relationship to the recipient (partner, family member, friend).

Type of Participation

Interview

Treatment

Transplantation

Topic

Caregivers

Location

All provinces and territories

Related studies

  • Promoting shared decision making for people with advanced chronic kidney disease

    Overview:

    Study type: Focus Group

    August 8, 2024

  • Improving the Care and Experiences of Living Kidney Donors

    Overview: Seeking family physicians and transplant healthcare professionals for an online interview that will help develop tools to improve the experiences, care, and outcomes of living kidney donors.

    Study type: Interview

    July 25, 2024

  • Phase 3 Pneumococcal Vaccine Study for Children & Adolescents at High Risk (STRIDE-13)

    Overview: STRIDE-13 is a pneumococcal vaccine research trial for children and adolescents with chronic disease (or chronic medical conditions).

    Study type: Clinical Trial

    July 11, 2024